Aldevron

Fargo, ND
Find alternatives to Aldevron for Plasmid →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
80.3
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ✓ SEC Filings (24) ✓ Press (2) ○ EMA GMP ○ MHRA GMP

Quick Facts: Aldevron

Signal Score
80.3/100 (as of 2026-10-29)
Quality Compliance
100.0/100
Headquarters
Fargo, ND
Modalities
Plasmid, mRNA
Active Programs
No ClinicalTrials.gov matches confirmed — 1 partnership signal in press (announcements, not verified)
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Aldevron

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2024-11-08)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesPlasmid, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Financial Stability 68.0
Parent company: Danaher Corporation
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
24 SEC filings with industry mentions on record (shown, not scored)
SEC Filings24 with industry mentions (not scored)
Parent company: Danaher Corporation
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Fargo, ND
Modalities: Plasmid, mRNA
Capacity assessment: 58.0/100
Sites: Fargo, ND
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals2 articles (not scored)
1 manufacturing site: Fargo, ND
Modalities: Plasmid, mRNA
Capacity assessment: 58.0/100

Aldevron FDA Inspection History

2024-11
NAI VAI OAI
Date Site Type 483 citations posted Classification
2024-11-08
Aldevron LLC
Prairie Rose, North Dakota Facility-linked
Vaccines and Allergenic Products Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Hiring Activity 35 open roles Beta

From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
35
open roles
24
in manufacturing, quality, PD/MSAT, engineering or regulatory (69%)
Trend from Dec 1, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 30, 2027.
Since Nov 19, 2026: 4 new postings, 1439 taken down.
What this may mean
  • 11 of the 27 openings at Fargo, North Dakota, United States of America are in quality (QA/QC). That fits added testing or batch-release work, but it can also be normal turnover.
  • There is an open site-leadership posting (Site Director Fargo GMP, Fargo, North Dakota, United States of America). Openings like this are routine and have many causes, such as a promotion, a reorganization or a new site.
  • 1 posting use start-up or expansion wording in the title. Read the posting before assuming a new facility; the wording is sometimes routine.
  • 3 job titles mention mRNA (Fargo, North Dakota, United States of America; Raleigh, North Carolina, United States of America / Fargo, North Dakota, United States of America / Waltham, Massachusetts, United States of America). That points to mRNA work there as of Nov 20, 2026, not to its size or stage.
By function
Manufacturing & operations 6
Quality (QA / QC) 11
Process development & MSAT 4
Engineering & facilities 3
Commercial, BD & client projects 6
Other (finance, HR, IT, other) 5
By site
Fargo, North Dakota, United States of America profile site
5 mfg/ops · 11 QA/QC · 4 PD/MSAT · 2 eng. · 5 other
27
Coralville, Iowa, United States of America / Boulder, Colorado, United States o…
1 mfg/ops · 1 other
2
Austin, Texas, United States of America / Coralville, Iowa, United States of Am…
· 1 other
1
Chicago, Illinois, United States of America / Atlanta, Georgia, United States o…
· 1 other
1
Deer Park, Illinois, United States of America / Alexandria, Virginia, United St…
· 1 other
1
Marlborough, Massachusetts, United States of America / Chaska, Minnesota, Unite…
· 1 other
1
Raleigh, North Carolina, United States of America / Fargo, North Dakota, United…
· 1 eng.
1
+ 1 more location
Modality words in job titles
mRNA3Plasmid DNA1
Notable roles
Site Director Fargo GMP Site leadership · Fargo, North Dakota, United States of America
Sr. Program Manager (Protein and mRNA Mfg., Greenfield Facility Expansion) Start-up / expansion wording · Raleigh, North Carolina, United...
Sr Director Finance Operations and Manufacturing USA Remote Senior operations / quality role · Coralville, Iowa, United States of...
Latest postings
Sr. Program Manager (Protein and mRNA Mfg., Greenfield Facility Expansion) Engineering & facilities · Raleigh, North Carolina, United... · posted Nov 20, 2026
Scientist Method Validation Process development & MSAT · Fargo, North Dakota, United States of America · posted Nov 20, 2026
Production Supervisor, mRNA - Research Grade Manufacturing & operations · Fargo, North Dakota, United States of America · posted Nov 20, 2026
Analyst I Method Validation Quality (QA / QC) · Fargo, North Dakota, United States of America · posted Nov 20, 2026
eQMS Project Manager Commercial, BD & client projects · Fargo, North Dakota, United States of America · posted Nov 19, 2026
Site Director Fargo GMP Other (finance, HR, IT, other) · Fargo, North Dakota, United States of America · posted Nov 19, 2026
Sterility Assurance Manager Other (finance, HR, IT, other) · Fargo, North Dakota, United States of America · posted Nov 18, 2026
Scientist I R&D Process development & MSAT · Fargo, North Dakota, United States of America · posted Nov 18, 2026
Order Management Coordinator I Other (finance, HR, IT, other) · Fargo, North Dakota, United States of America · posted Nov 18, 2026
Senior Client Quality Manager Quality (QA / QC) · Fargo, North Dakota, United States of America · posted Nov 17, 2026
Inside Sales Representative Service Commercial, BD & client projects · Deer Park, Illinois, United States... · posted Nov 17, 2026
Biomanufacturing Operator I Research Grade Manufacturing & operations · Fargo, North Dakota, United States of America · posted Nov 11, 2026
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Aldevron (Fargo, ND) on the Danaher Phenom board; the sitemap has no location, so it needs JSON-LD locations (backfill 600 pages a day)). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: jobs.danaher.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Financial Intelligence

10-Q 2026-10-21 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements, replacing equipment, purchasing buildings, supporting new product development and improving information technology systems."
8-K 2026-10-21 0 keyword mentions
"Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION: On October 21, 2026, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the quarter ended September 25, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Danaher pursuant to Item 2.02 of Form 8-K."
8-K 2026-10-13 0 keyword mentions
"Item 5.02: DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS"
"Item 8.01 OTHER EVENTS: As previously disclosed in that certain Current Report on Form 8-K filed by the Company on August 3, 2026, on August 4, 2026, Steven M. Rales, Chairman of the Board and co-founder of the Company, and Mitchell P. Rales, Chairman of the Executive Committee and co-founder of the Company, were each granted restricted stock units with respect to 500,000 shares of the Company’s common stock (the “Founder RSUs”) as well as awards of stock options."
8-K 2026-08-03 0 keyword mentions
"Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS: Appointment of Julie Sawyer Montgomery as President and Chief Executive Officer"
"Item 5.02 Transition of Rainer M. Blair: In connection with Ms. Sawyer Montgomery’s succession, on August 3, 2026, the Company also announced that, effective as of the Effective Date, Rainer M. Blair will cease serving as President and CEO of the Company, and will resign as a member of the Board and from each of the Executive, Finance and Science & Technology Committees of the Board. As further discussed below, to support the transition, Mr. Blair has agreed to continue employment as Senior Advi"
"Item 5.02 Special Equity Awards: On July 31, 2026, the Compensation Committee of the Board (the “Compensation Committee”) approved a Long-Term Growth Award to Matthew Gugino, the Company’s Chief Financial Officer, with a target award value of $12,500,000 and on the same terms as described above for the Long-Term Growth Award granted to Ms. Sawyer Montgomery."
10-Q 2026-07-21 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements, replacing equipment, purchasing buildings, supporting new product development and improving information technology systems."
8-K 2026-07-21 0 keyword mentions
"Item 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION: On July 21, 2026, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the quarter ended June 26, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Danaher pursuant to Item 2.02 of Form 8-K."
8-K 2026-06-03 0 keyword mentions
"Item 8.01 OTHER EVENTS: On June 3, 2026, Danaher Corporation, a Delaware corporation (the “Company”), and its wholly owned subsidiary DH Masi Finance Inc., a Delaware corporation (the “Issuer”), entered into a note purchase and guaranty agreement among the Company, the Issuer and the institutional accredited investors named therein (the “Note Purchase Agreement”), relating to the issuance and sale of (i) CHF 119,500,000 aggregate principal amount of the Issuer’s 1.65% Senior Notes, Series A due "
8-K 2026-04-29 0 keyword mentions
10-Q 2026-04-21 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements, replacing equipment, purchasing buildings, supporting new product development and improving information technology systems."
8-K 2026-04-21 0 keyword mentions
8-K 2026-04-17 0 keyword mentions
10-K 2026-02-24 13 keyword mentions
"government could also control our allocation of manufacturing capacity."
"These therapeutics include protein-based and other biological therapies as well as a new emerging class of highly-targeted therapies such as cell and gene therapies and nucleic acid-based therapies."
"Typical users of these products and services include pharmaceutical and biopharmaceutical companies, translational medicine institutions, biotechnology companies and contract manufacturing organizations."
8-K 2026-02-17 0 keyword mentions
8-K 2026-02-10 0 keyword mentions
8-K 2026-01-28 0 keyword mentions
8-K 2026-01-12 0 keyword mentions
8-K 2025-11-06 0 keyword mentions
10-Q 2025-10-21 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, increasing manufacturing capacity, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
10-Q 2025-07-22 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"29 Table of Contents LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
10-Q 2025-04-22 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
10-K 2025-02-20 12 keyword mentions
"government could also control our allocation of manufacturing capacity."
"These therapeutics include protein-based and other biological therapies as well as a new emerging class of highly-targeted therapies such as cell and gene therapies and nucleic acid-based therapies."
"Typical users of these products and services include pharmaceutical and biopharmaceutical companies, translational medicine institutions, biotechnology companies and contract manufacturing organizations."
10-Q 2024-10-22 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, replacing equipment, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, supporting new product development and improving IT systems."
10-Q 2024-07-23 5 keyword mentions
"government could also control our allocation of manufacturing capacity."
"Additionally, while the Company believes that emerging biotech customers are continuing to manage their liquidity, we also believe they are prioritizing select cell and gene therapy projects, and we further believe that the improvement in the overall funding environment in the period is a positive leading indicator for these customers."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
10-Q 2024-04-23 3 keyword mentions
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, replacing equipment, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, supporting new product development and improving IT systems."
Source: SEC EDGAR · Retrieved Nov 21, 2026

Company Signals 2 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-05-06
Aldevron Joins EGMEDC to Turn Genomic Promise Into European Practice - CRISPR Medicine News
Aldevron Joins EGMEDC to Turn Genomic Promise Into European Practice  CRISPR Medicine News
partnership 2026-04-14
Aldevron Named 2026 CDMO Leadership Awards Winner in the Small/Mid-Size Cell & Gene Therapy Category - PR.com
Aldevron Named 2026 CDMO Leadership Awards Winner in the Small/Mid-Size Cell & Gene Therapy Category  PR.com

Frequently Asked Questions About Aldevron

How many FDA inspections does Aldevron have on record?
CDMO Signal tracks 1 FDA inspection for Aldevron, sourced from the FDA inspection database. See the full inspection history above.
Has Aldevron received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Aldevron.
What is Aldevron's CDMO Signal Score?
Aldevron has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating Aldevron for a manufacturing program?
Use the free AI matchmaker to compare Aldevron against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Plasmid CDMOs → mRNA CDMOs →

Similar CDMOs

ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
Kaneka Eurogentec
Seraing, BE
Signal Score: 81.6
mRNA, Plasmid, Oligonucleotide
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein

Compare Aldevron with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Aldevron
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.